Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers.

Sectors
Healthcare
Life Sciences
First Invested
2017
Public/PIPES
Company Status
IPO/Public
NASDAQ: XFOR